FOLH1 and prostate cancer: Preclinical findings in mice receiving [177Lu]Lu-PSMA-617 RLT have proven that a higher density of the transmembrane glycoprotein PSMA on prostate cancer cells is associated with increased ligand internalization and treatment efficacy [19].